First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 Asian subgroup analysis

Oh, D-y.; Yen, C. J.; Bai, Y.; Ryu, M. H.; Lee, J.; Li, J.; Yang, L.; Yasui, H.; Yabusaki, H.; Lam, K. O.; Yamaguchi, K.; Yeh, K-h.; Wang, A.; Leconte, P.; Bhagia, P.; Rha, S. Y.

doi:10.1016/j.annonc.2025.10.103

상세 보기

First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 Asian subgroup analysis

Oh, D-y.;
Yen, C. J.;
Bai, Y.;
Ryu, M. H.;
Lee, J.;
외 11명

Citations

WEB OF SCIENCE

0

Citations

SCOPUS

0

제목: First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 Asian subgroup analysis

저자: Oh, D-y.; Yen, C. J.; Bai, Y.; Ryu, M. H.; Lee, J.; Li, J.; Yang, L.; Yasui, H.; Yabusaki, H.; Lam, K. O.; Yamaguchi, K.; Yeh, K-h.; Wang, A.; Leconte, P.; Bhagia, P.; Rha, S. Y.

DOI: 10.1016/j.annonc.2025.10.103

발행일: 2025-12

유형: Meeting Abstract

저널명: Annals of Oncology

권: 36

ScholarWorks@성균관대학교

상세 보기